Skip to main content
Erschienen in: Supportive Care in Cancer 8/2018

03.05.2018 | Review Article

Quality of life in oropharyngeal cancer: a structured review of the literature

verfasst von: Evelyne Roets, Karina Tukanova, Anouk Govarts, Pol Specenier

Erschienen in: Supportive Care in Cancer | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To summarize the literature on quality of life (QoL) in patients with oropharyngeal squamous cell carcinoma (OPSCC).

Methods

The PubMed database was searched using the inclusion criteria “oropharyngeal cancer,” “quality of life,” “human,” and “English,” the exclusion criterion “recurrent,” and publication date between January 1, 2005 and October 26, 2015.

Results

The search yielded 98 articles of which 17 fulfilled all selection criteria. Intensity-modulated radiotherapy (IMRT) showed a better outcome for several QoL domains and was superior to chemoradiotherapy (CRT) in some studies. At 12-month follow up, deterioration of QoL was seen in a smaller proportion of patients after surgery and postoperative radiotherapy (S&PORT) in comparison to CRT. For all treatment modalities, the most important worsening for several QoL domains was seen at 3 months. Stage III/IV patients experienced a greater deterioration of QoL scores for most scores. No consistent results were reported for the correlation between xerostomia assessed with QoL questionnaires and objective swallowing function assessed with modified barium swallow videofluoroscopy.

Conclusion

The different tools used for the assessment of patient-reported QoL and objective measurement of functional outcome make it difficult to evaluate the effect of different treatment modalities. In general, we can conclude that a non-surgical approach is associated with worse QoL scores. IMRT minimizes radiation to the surrounding tissue and therefore has a better outcome in several QoL domains in comparison to conventional RT.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Control UfIC (2014) Locally advanced head and neck cancer, review of cancer medicines on the WHO list of essential medicines Control UfIC (2014) Locally advanced head and neck cancer, review of cancer medicines on the WHO list of essential medicines
2.
Zurück zum Zitat Vainshtein JM, Moon DH, Feng FY, Chepeha DB, Eisbruch A, Stenmark MH (2015) Long-term quality of life after swallowing and salivary-sparing chemo-intensity modulated radiation therapy in survivors of human papillomavirus-related oropharyngeal cancer. Int J Radiat Oncol Biol Phys 91(5):925–933CrossRefPubMedPubMedCentral Vainshtein JM, Moon DH, Feng FY, Chepeha DB, Eisbruch A, Stenmark MH (2015) Long-term quality of life after swallowing and salivary-sparing chemo-intensity modulated radiation therapy in survivors of human papillomavirus-related oropharyngeal cancer. Int J Radiat Oncol Biol Phys 91(5):925–933CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Oates J, Davies S, Roydhouse JK, Fethney J, White K (2014) The effect of cancer stage and treatment modality on quality of life in oropharyngeal cancer. Laryngoscope 124(1):151–158CrossRefPubMed Oates J, Davies S, Roydhouse JK, Fethney J, White K (2014) The effect of cancer stage and treatment modality on quality of life in oropharyngeal cancer. Laryngoscope 124(1):151–158CrossRefPubMed
4.
Zurück zum Zitat Al-Mamgani A, van Rooij P, Tans L, Verduijn GM, Sewnaik A, Baatenburg de Jong RJA (2013) prospective evaluation of patient-reported quality-of-life after (chemo)radiation for oropharyngeal cancer: which patients are at risk of significant quality-of-life deterioration? Radiother Oncol 106(3):359–363CrossRefPubMed Al-Mamgani A, van Rooij P, Tans L, Verduijn GM, Sewnaik A, Baatenburg de Jong RJA (2013) prospective evaluation of patient-reported quality-of-life after (chemo)radiation for oropharyngeal cancer: which patients are at risk of significant quality-of-life deterioration? Radiother Oncol 106(3):359–363CrossRefPubMed
5.
Zurück zum Zitat Hunter KU, Schipper M, Feng FY, Lyden T, Haxer M, Murdoch-Kinch CA, Cornwall B, Lee CSY, Chepeha DB, Eisbruch A (2013) Toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer: prospective study of patient-reported, observer-rated, and objective outcomes. Int J Radiat Oncol Biol Phys 85(4):935–940CrossRefPubMed Hunter KU, Schipper M, Feng FY, Lyden T, Haxer M, Murdoch-Kinch CA, Cornwall B, Lee CSY, Chepeha DB, Eisbruch A (2013) Toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer: prospective study of patient-reported, observer-rated, and objective outcomes. Int J Radiat Oncol Biol Phys 85(4):935–940CrossRefPubMed
6.
Zurück zum Zitat Kendall KA, Kosek SR, Tanner K (2014) Quality-of-life scores compared to objective measures of swallowing after oropharyngeal chemoradiation. Laryngoscope 124(3):682–687CrossRefPubMed Kendall KA, Kosek SR, Tanner K (2014) Quality-of-life scores compared to objective measures of swallowing after oropharyngeal chemoradiation. Laryngoscope 124(3):682–687CrossRefPubMed
7.
Zurück zum Zitat Broglie MA, Soltermann A, Haile SR, Roosli C, Huber GF, Schmid S et al (2013) Quality of life of oropharyngeal cancer patients with respect to treatment strategy and p16-positivity. Laryngoscope 123(1):164–170CrossRefPubMed Broglie MA, Soltermann A, Haile SR, Roosli C, Huber GF, Schmid S et al (2013) Quality of life of oropharyngeal cancer patients with respect to treatment strategy and p16-positivity. Laryngoscope 123(1):164–170CrossRefPubMed
8.
Zurück zum Zitat Yao M, Karnell LH, Funk GF, Lu H, Dornfeld K, Buatti JM (2007) Health-related quality-of-life outcomes following IMRT versus conventional radiotherapy for oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 69(5):1354–1360CrossRefPubMed Yao M, Karnell LH, Funk GF, Lu H, Dornfeld K, Buatti JM (2007) Health-related quality-of-life outcomes following IMRT versus conventional radiotherapy for oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 69(5):1354–1360CrossRefPubMed
9.
Zurück zum Zitat Mowry SE, Tang C, Sadeghi A, Wang MB (2010) Standard chemoradiation versus intensity-modulated chemoradiation: a quality of life assessment in oropharyngeal cancer patients. Eur Arch Oto-Rhino-Laryngology Off J Eur Fed Oto-Rhino-Laryngological Societies (EUFOS) Aff Ger Soc Oto-Rhino-Laryngology. Head Neck Surg. 267(7):1111–1116 Mowry SE, Tang C, Sadeghi A, Wang MB (2010) Standard chemoradiation versus intensity-modulated chemoradiation: a quality of life assessment in oropharyngeal cancer patients. Eur Arch Oto-Rhino-Laryngology Off J Eur Fed Oto-Rhino-Laryngological Societies (EUFOS) Aff Ger Soc Oto-Rhino-Laryngology. Head Neck Surg. 267(7):1111–1116
10.
Zurück zum Zitat Mowry SE, Ho A, Lotempio MM, Sadeghi A, Blackwell KE, Wang MB (2006) Quality of life in advanced oropharyngeal carcinoma after chemoradiation versus surgery and radiation. Laryngoscope 116(9):1589–1593CrossRefPubMed Mowry SE, Ho A, Lotempio MM, Sadeghi A, Blackwell KE, Wang MB (2006) Quality of life in advanced oropharyngeal carcinoma after chemoradiation versus surgery and radiation. Laryngoscope 116(9):1589–1593CrossRefPubMed
11.
Zurück zum Zitat Gillespie MB, Brodsky MB, Day TA, Sharma AK, Lee FS, Martin-Harris B (2005) Laryngeal penetration and aspiration during swallowing after the treatment of advanced oropharyngeal cancer. Arch Otolaryngol Head Neck Surg 131(7):615–619CrossRefPubMed Gillespie MB, Brodsky MB, Day TA, Sharma AK, Lee FS, Martin-Harris B (2005) Laryngeal penetration and aspiration during swallowing after the treatment of advanced oropharyngeal cancer. Arch Otolaryngol Head Neck Surg 131(7):615–619CrossRefPubMed
12.
Zurück zum Zitat Thomas L, Jones TM, Tandon S, Katre C, Lowe D, Rogers SN (2008) An evaluation of the University of Washington Quality of Life swallowing domain following oropharyngeal cancer. Eur Arch Otorhinolaryngol 265(Suppl 1):S29–S37CrossRefPubMed Thomas L, Jones TM, Tandon S, Katre C, Lowe D, Rogers SN (2008) An evaluation of the University of Washington Quality of Life swallowing domain following oropharyngeal cancer. Eur Arch Otorhinolaryngol 265(Suppl 1):S29–S37CrossRefPubMed
13.
Zurück zum Zitat Vainshtein JM, Griffith KA, Feng FY, Vineberg KA, Chepeha DB, Eisbruch A (2014) Patient-reported voice and speech outcomes after whole-neck intensity modulated radiation therapy and chemotherapy for oropharyngeal cancer: prospective longitudinal study. Int J Radiat Oncol Biol Phys 89(5):973–980CrossRefPubMed Vainshtein JM, Griffith KA, Feng FY, Vineberg KA, Chepeha DB, Eisbruch A (2014) Patient-reported voice and speech outcomes after whole-neck intensity modulated radiation therapy and chemotherapy for oropharyngeal cancer: prospective longitudinal study. Int J Radiat Oncol Biol Phys 89(5):973–980CrossRefPubMed
14.
Zurück zum Zitat Thomas L, Jones TM, Tandon S, Carding P, Lowe D, Rogers S (2009) Speech and voice outcomes in oropharyngeal cancer and evaluation of the University of Washington Quality of Life speech domain. Clin Otolaryngol Off J ENT-UK Off J Neth Soc Oto-Rhino-Laryngology Cervico-Facial Surg. 34(1):34–42 Thomas L, Jones TM, Tandon S, Carding P, Lowe D, Rogers S (2009) Speech and voice outcomes in oropharyngeal cancer and evaluation of the University of Washington Quality of Life speech domain. Clin Otolaryngol Off J ENT-UK Off J Neth Soc Oto-Rhino-Laryngology Cervico-Facial Surg. 34(1):34–42
15.
Zurück zum Zitat Elfring TT, Boliek CA, Seikaly H, Harris J, Rieger JM (2012) Sensory outcomes of the anterior tongue after lingual nerve repair in oropharyngeal cancer. J Oral Rehabil 39(3):170–181CrossRefPubMed Elfring TT, Boliek CA, Seikaly H, Harris J, Rieger JM (2012) Sensory outcomes of the anterior tongue after lingual nerve repair in oropharyngeal cancer. J Oral Rehabil 39(3):170–181CrossRefPubMed
16.
Zurück zum Zitat Teguh DN, Levendag PC, Voet P, van der Est H, Noever I, de Kruijf W, van Rooij P, Schmitz PIM, Heijmen BJ (2008) Trismus in patients with oropharyngeal cancer: relationship with dose in structures of mastication apparatus. Head Neck 30(5):622–630CrossRefPubMed Teguh DN, Levendag PC, Voet P, van der Est H, Noever I, de Kruijf W, van Rooij P, Schmitz PIM, Heijmen BJ (2008) Trismus in patients with oropharyngeal cancer: relationship with dose in structures of mastication apparatus. Head Neck 30(5):622–630CrossRefPubMed
17.
Zurück zum Zitat Levendag PC, Teguh DN, Voet P, van der Est H, Noever I, de Kruijf WJ et al (2007) Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose-effect relationship. Radiother Oncol 85(1):64–73CrossRefPubMed Levendag PC, Teguh DN, Voet P, van der Est H, Noever I, de Kruijf WJ et al (2007) Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose-effect relationship. Radiother Oncol 85(1):64–73CrossRefPubMed
18.
Zurück zum Zitat Dziegielewski PT, Teknos TN, Durmus K, Old M, Agrawal A, Kakarala K, Marcinow A, Ozer E (2013) Transoral robotic surgery for oropharyngeal cancer: long-term quality of life and functional outcomes. JAMA Otolaryngol Head Neck Surg 139(11):1099–1108CrossRefPubMedPubMedCentral Dziegielewski PT, Teknos TN, Durmus K, Old M, Agrawal A, Kakarala K, Marcinow A, Ozer E (2013) Transoral robotic surgery for oropharyngeal cancer: long-term quality of life and functional outcomes. JAMA Otolaryngol Head Neck Surg 139(11):1099–1108CrossRefPubMedPubMedCentral
Metadaten
Titel
Quality of life in oropharyngeal cancer: a structured review of the literature
verfasst von
Evelyne Roets
Karina Tukanova
Anouk Govarts
Pol Specenier
Publikationsdatum
03.05.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 8/2018
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-018-4227-9

Weitere Artikel der Ausgabe 8/2018

Supportive Care in Cancer 8/2018 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.